$3.69 -$0.06 (-1.6%)

04:00 PM EST on 11/20/19

Novavax, Inc. (NASDAQ:NVAX)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

Current Price $3.69 Mkt Cap $87.9M
Open $3.78 P/E Ratio 0.00
Prev. Close $3.75 Div. (Yield) $0.00 (0.0%)
Daily Range $3.69 - $3.81 Volume 480,016
52-Wk Range $3.69 - $48.80 Avg. Daily Vol. 574,819


How do you think NASDAQ:NVAX will perform against the market?

Add Stock to CAPS Watchlist

All Players

294 Outperform
89 Underperform

All-Star Players

32 Outperform
16 Underperform

Wall Street

5 Outperform
2 Underperform

Top NASDAQ:NVAX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFSaintCroix (98.95)
Submitted November 24, 2017

The company has two billion-dollar drugs in the pipeline.The first is a vaccine to combat RSV, the most common cause of bronchitis and pneumonia in babies. This is a multi-billion dollar drug. We are all waiting on phase 3 results.What made it a… More

rhinomaj (92.99)
Submitted August 04, 2009

The investment premise for this and a number of the speculative H1N1 stock plays are based on two faulty premises. 1] That there will be a substantial shortage of vaccine from the already contracted Pharma including GSK, Sanofi, Medi. 2] that these… More

Recent Community Commentary

Read the most recent pitches from players about NVAX.


Member Avatar FVelociraptor (99.92) Submitted: 11/13/2019 6:03:19 PM : Underperform Start Price: $4.19 NASDAQ:NVAX Score: +12.55



Member Avatar TMFGBudwell (< 20) Submitted: 1/2/2018 2:24:13 PM : Outperform Start Price: $1.28 NASDAQ:NVAX Score: +172.47

RSV and flu vaccines


Member Avatar TMFSaintCroix (98.95) Submitted: 11/24/2017 1:18:42 PM : Outperform Start Price: $1.39 NASDAQ:NVAX Score: +128.54

The company has two billion-dollar drugs in the pipeline.

The first is a vaccine to combat RSV, the most common cause of bronchitis and pneumonia in babies. This is a multi-billion dollar drug. We are all waiting on phase 3 results.

What made it a buying opportunity is the stock getting hammered because of bad news in the phase 2 trials of the RSV drug. Same drug, but a different set of patients: old people.

The company's explanation for the bad news is that control group numbers for the disease was less than what the company was expecting. The efficacy was off because people in the control group didn't get sick, either.

Whether or not you buy that explanation--and I do--it's important to realize that young babies and very old people are two different classes of patients when it comes to RSV. That's why they're running two different trials, after all. So the idea that bad news in the phase 2 trial with old people means bad news for the phase 3 trial in babies isn't at all true.

Anyway, this stock has been a battle over the future of the RSV drug.

But what's making the stock take off now is drug #2.

Out of nowhere the company has had fantastic success with its NanoFlu drug. It's producing superior hemagglutinin antigen inhibition antibody responses (in ferrets) compared to Sanofi's flu vaccines. The numbers have been so impressive the company is rushing the drug into clinical trials. It is now in phase 1/phase 2. They could be filing for approval in 2019.

It's excitement over the flu vaccine--another multi-billion dollar market--that is making the stock jump right now.


Find the members with the highest scoring picks in NVAX.

Score Leader


Bigeric42 (99.94) Score: +1,174.04

The Score Leader is the player with the highest score across all their picks in NVAX.

Member Name Member
Call Time
Score Commentary
TheAnamalous 43.74 3/1/2019 Outperform 5Y $0.70 +425.72% +11.17% +414.55 0 Comment
marksaal < 20 4/28/2009 Underperform 1Y $3.11 +18.65% +269.46% +250.81 1 Comment
AGCAPS < 20 4/28/2009 8/11/2011 Underperform 5Y $3.11 +18.65% +269.46% +250.81 0 Comment
rhinomaj 92.99 7/29/2009 Underperform 3M $4.75 -22.32% +219.68% +241.99 3 Comments
rjallan < 20 9/8/2009 Underperform 3M $5.74 -35.71% +203.06% +238.78 0 Comment
ReadEmAnWeep 43.17 8/11/2009 Underperform 5Y $5.09 -27.50% +210.56% +238.06 0 Comment
Zippidy2 49.19 8/6/2009 Underperform 5Y $4.91 -24.85% +212.67% +237.52 0 Comment
storystockshort 97.86 4/29/2009 Underperform 5Y $2.93 +25.94% +262.84% +236.91 0 Comment
examinebeyond 30.43 4/29/2009 Underperform 3W $2.93 +25.94% +262.84% +236.91 0 Comment
2iQPureAlpha 93.22 4/29/2009 Underperform 5Y $2.93 +25.94% +262.84% +236.91 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NVAX.